- Home
- Publications
- Publication Search
- Publication Details
Title
Revisiting neoadjuvant therapy in non-small-cell lung cancer
Authors
Keywords
-
Journal
LANCET ONCOLOGY
Volume 22, Issue 11, Pages e501-e516
Publisher
Elsevier BV
Online
2021-11-02
DOI
10.1016/s1470-2045(21)00383-1
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
- (2021) Hyuna Sung et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Neoadjuvant nivolumab or nivolumab plus ipilimumab in operable non-small cell lung cancer: the phase 2 randomized NEOSTAR trial
- (2021) Tina Cascone et al. NATURE MEDICINE
- OA06.06 Clinical/Biomarker Data for Neoadjuvant Atezolizumab in Resectable Stage IB-IIIB NSCLC: Primary Analysis in the LCMC3 Study
- (2021) D. Carbone et al. Journal of Thoracic Oncology
- IASLC MULTIDISCIPLINARY RECOMMENDATIONS FOR PATHOLOGIC ASSESSMENT OF LUNG CANCER RESECTION SPECIMENS FOLLOWING NEOADJUVANT THERAPY
- (2020) William D. Travis et al. Journal of Thoracic Oncology
- Neoadjuvant PD-1 inhibitor (Sintilimab) in NSCLC
- (2020) Shugeng Gao et al. Journal of Thoracic Oncology
- Feasibility of multi-parametric magnetic resonance imaging combined with machine learning in the assessment of necrosis of osteosarcoma after neoadjuvant chemotherapy: a preliminary study
- (2020) Bingsheng Huang et al. BMC CANCER
- Gefitinib as neoadjuvant therapy for resectable stage II-IIIA non–small cell lung cancer: A phase II study
- (2020) Yang Zhang et al. JOURNAL OF THORACIC AND CARDIOVASCULAR SURGERY
- Neoadjuvant atezolizumab and chemotherapy in patients with resectable non-small-cell lung cancer: an open-label, multicentre, single-arm, phase 2 trial
- (2020) Catherine A Shu et al. LANCET ONCOLOGY
- Imaging-based target volume reduction in chemoradiotherapy for locally advanced non-small-cell lung cancer (PET-Plan): a multicentre, open-label, randomised, controlled trial
- (2020) Ursula Nestle et al. LANCET ONCOLOGY
- The Effect of Advances in Lung-Cancer Treatment on Population Mortality
- (2020) Nadia Howlader et al. NEW ENGLAND JOURNAL OF MEDICINE
- Report on computational assessment of Tumor Infiltrating Lymphocytes from the International Immuno-Oncology Biomarker Working Group
- (2020) Mohamed Amgad et al. npj Breast Cancer
- 1237MO SAKK 16/14: Anti-PD-L1 antibody durvalumab in addition to neoadjuvant chemotherapy in patients with stage IIIA (N2) non-small cell lung cancer (NSCLC) – A multicenter single-arm phase II trial
- (2020) S.I. Rothschild et al. ANNALS OF ONCOLOGY
- 1214O Neoadjuvant durvalumab in resectable non-small cell lung cancer (NSCLC): Preliminary results from a multicenter study (IFCT-1601 IONESCO)
- (2020) M. Wislez et al. ANNALS OF ONCOLOGY
- 1215O - SC Neoadjuvant atezolizumab (A) for resectable non-small cell lung cancer (NSCLC): Results from the phase II PRINCEPS trial
- (2020) B. Besse et al. ANNALS OF ONCOLOGY
- Ipilimumab plus nivolumab and chemoradiotherapy followed by surgery in patients with resectable and borderline resectable T3-4N0–1 non-small cell lung cancer: the INCREASE trial
- (2020) Chris Dickhoff et al. BMC CANCER
- Neoadjuvant Chemotherapy Increases Cytotoxic T cell, Tissue Resident Memory T cell and B Cell Infiltration in Resectable Non-Small Cell Lung Cancer
- (2020) Pierre-Olivier Gaudreau et al. Journal of Thoracic Oncology
- Neoadjuvant chemotherapy and nivolumab in resectable non-small-cell lung cancer (NADIM): an open-label, multicentre, single-arm, phase 2 trial
- (2020) Mariano Provencio et al. LANCET ONCOLOGY
- Osimertinib in Resected EGFR-Mutated Non–Small-Cell Lung Cancer
- (2020) Yi-Long Wu et al. NEW ENGLAND JOURNAL OF MEDICINE
- KEAP1/NFE2L2 mutations predict lung cancer radiation resistance that can be targeted by glutaminase inhibition
- (2020) Michael S Binkley et al. Cancer Discovery
- Novel, non-invasive imaging approach to identify patients with advanced non-small cell lung cancer at risk of hyperprogressive disease with immune checkpoint blockade
- (2020) Pranjal Vaidya et al. Journal for ImmunoTherapy of Cancer
- Measuring the Integration of Stereotactic Ablative Radiotherapy Plus Surgery for Early-Stage Non–Small Cell Lung Cancer
- (2019) David A. Palma et al. JAMA Oncology
- Third generation EGFR TKI landscape for metastatic EGFR mutant non-small cell lung cancer (NSCLC)
- (2019) Aaron C. Tan et al. Expert Review of Anticancer Therapy
- Erlotinib Versus Gemcitabine Plus Cisplatin as Neoadjuvant Treatment of Stage IIIA-N2 EGFR-Mutant Non–Small-Cell Lung Cancer (EMERGING-CTONG 1103): A Randomized Phase II Study
- (2019) Wen-Zhao Zhong et al. JOURNAL OF CLINICAL ONCOLOGY
- Effect of Pembrolizumab After Stereotactic Body Radiotherapy vs Pembrolizumab Alone on Tumor Response in Patients With Advanced Non–Small Cell Lung Cancer
- (2019) Willemijn S. M. E. Theelen et al. JAMA Oncology
- P1.17-07 Neoadjuvant Gefitinib in Resectable Early Stage EGFR Mutant Non-Small Cell Lung Cancer (NSCLC): A Window-of-Opportunity Study
- (2019) A. Tan et al. Journal of Thoracic Oncology
- P2.04-92 Neoadjuvant Durvalumab With or Without Sub-Ablative Stereotactic Radiotherapy (SBRT) in Patients with Resectable NSCLC (NCT02904954)
- (2019) N. Altorki et al. Journal of Thoracic Oncology
- The immunotherapeutic landscape in non–small cell lung cancer and its surgical horizons
- (2019) Kristen E. Rhodin et al. JOURNAL OF THORACIC AND CARDIOVASCULAR SURGERY
- Pathologic features of response to neoadjuvant anti-PD-1 in resected non-small-cell lung carcinoma: a proposal for quantitative immune-related pathologic response criteria (irPRC)
- (2018) T R Cottrell et al. ANNALS OF ONCOLOGY
- Effects of surgery and anesthetic choice on immunosuppression and cancer recurrence
- (2018) Ryungsa Kim Journal of Translational Medicine
- Gefitinib versus vinorelbine plus cisplatin as adjuvant treatment for stage II–IIIA (N1–N2) EGFR -mutant NSCLC (ADJUVANT/CTONG1104): a randomised, open-label, phase 3 study
- (2018) Wen-Zhao Zhong et al. LANCET ONCOLOGY
- Neoadjuvant PD-1 Blockade in Resectable Lung Cancer
- (2018) Patrick M. Forde et al. NEW ENGLAND JOURNAL OF MEDICINE
- Elucidating the genomic architecture of Asian EGFR-mutant lung adenocarcinoma through multi-region exome sequencing
- (2018) Rahul Nahar et al. Nature Communications
- Major pathologic response and RAD51 predict survival in lung cancer patients receiving neoadjuvant chemotherapy
- (2018) Apar Pataer et al. Cancer Medicine
- Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC
- (2018) Scott J. Antonia et al. NEW ENGLAND JOURNAL OF MEDICINE
- Erlotinib as Neoadjuvant Therapy in Stage IIIA (N2)EGFRMutation‐Positive Non‐Small Cell Lung Cancer: A Prospective, Single‐Arm, Phase II Study
- (2018) Liwen Xiong et al. ONCOLOGIST
- Initial results of pulmonary resection following neoadjuvant nivolumab in patients with resectable non-small cell lung cancer
- (2018) Matthew J. Bott et al. JOURNAL OF THORACIC AND CARDIOVASCULAR SURGERY
- Radiotherapy induces responses of lung cancer to CTLA-4 blockade
- (2018) Silvia C. Formenti et al. NATURE MEDICINE
- Neoadjuvant versus adjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma
- (2018) Christian U. Blank et al. NATURE MEDICINE
- Trastuzumab Emtansine for Residual Invasive HER2-Positive Breast Cancer
- (2018) Gunter von Minckwitz et al. NEW ENGLAND JOURNAL OF MEDICINE
- Pathologic Assessment After Neoadjuvant Chemotherapy for NSCLC: Importance and Implications of Distinguishing Adenocarcinoma From Squamous Cell Carcinoma
- (2018) Yang Qu et al. Journal of Thoracic Oncology
- Previous radiotherapy and the clinical activity and toxicity of pembrolizumab in the treatment of non-small-cell lung cancer: a secondary analysis of the KEYNOTE-001 phase 1 trial
- (2017) Narek Shaverdian et al. LANCET ONCOLOGY
- Phylogenetic ctDNA analysis depicts early-stage lung cancer evolution
- (2017) Christopher Abbosh et al. NATURE
- Radiotherapy and immunotherapy: a beneficial liaison?
- (2017) Ralph R. Weichselbaum et al. Nature Reviews Clinical Oncology
- Tracking the Evolution of Non–Small-Cell Lung Cancer
- (2017) Mariam Jamal-Hanjani et al. NEW ENGLAND JOURNAL OF MEDICINE
- TCR Repertoire Intratumor Heterogeneity in Localized Lung Adenocarcinomas: An Association with Predicted Neoantigen Heterogeneity and Postsurgical Recurrence
- (2017) Alexandre Reuben et al. Cancer Discovery
- Improved Efficacy of Neoadjuvant Compared to Adjuvant Immunotherapy to Eradicate Metastatic Disease
- (2016) J. Liu et al. Cancer Discovery
- Phase III Study of Surgery Versus Definitive Concurrent Chemoradiotherapy Boost in Patients With Resectable Stage IIIA(N2) and Selected IIIB Non–Small-Cell Lung Cancer After Induction Chemotherapy and Concurrent Chemoradiotherapy (ESPATUE)
- (2015) Wilfried Ernst Erich Eberhardt et al. JOURNAL OF CLINICAL ONCOLOGY
- Induction chemoradiation in stage IIIA/N2 non-small-cell lung cancer: a phase 3 randomised trial
- (2015) Miklos Pless et al. LANCET
- Preoperative chemotherapy for non-small-cell lung cancer: a systematic review and meta-analysis of individual participant data
- (2014) LANCET
- Pathological response after neoadjuvant chemotherapy in resectable non-small-cell lung cancers: proposal for the use of major pathological response as a surrogate endpoint
- (2014) Matthew D Hellmann et al. LANCET ONCOLOGY
- A phase 3 study of induction treatment with concurrent chemoradiotherapy versus chemotherapy before surgery in patients with pathologically confirmed N2 stage IIIA nonsmall cell lung cancer (WJTOG9903)
- (2012) Nobuyuki Katakami et al. CANCER
- Histopathologic Response Criteria Predict Survival of Patients with Resected Lung Cancer After Neoadjuvant Chemotherapy
- (2012) Apar Pataer et al. Journal of Thoracic Oncology
- Randomized Phase III Study of Surgery Alone or Surgery Plus Preoperative Cisplatin and Gemcitabine in Stages IB to IIIA Non–Small-Cell Lung Cancer
- (2011) Giorgio V. Scagliotti et al. JOURNAL OF CLINICAL ONCOLOGY
- Contemporary Results of Surgical Resection of Non-small Cell Lung Cancer After Induction Therapy: A Review of 549 Consecutive Cases
- (2011) Stephen A. Barnett et al. Journal of Thoracic Oncology
- Histopathological and immunohistochemical features associated with clinical response to neoadjuvant gefitinib therapy in early stage non-small cell lung cancer
- (2011) Humberto Lara-Guerra et al. LUNG CANCER
- Surgery With or Without Preoperative Paclitaxel and Carboplatin in Early-Stage Non–Small-Cell Lung Cancer: Southwest Oncology Group Trial S9900, an Intergroup, Randomized, Phase III Trial
- (2010) Katherine M.W. Pisters et al. JOURNAL OF CLINICAL ONCOLOGY
- Preoperative Chemotherapy Plus Surgery Versus Surgery Plus Adjuvant Chemotherapy Versus Surgery Alone in Early-Stage Non–Small-Cell Lung Cancer
- (2010) Enriqueta Felip et al. JOURNAL OF CLINICAL ONCOLOGY
- Randomized Phase III Trial of Vinorelbine Plus Cisplatin Compared With Observation in Completely Resected Stage IB and II Non–Small-Cell Lung Cancer: Updated Survival Analysis of JBR-10
- (2009) Charles A. Butts et al. JOURNAL OF CLINICAL ONCOLOGY
- Radiotherapy plus chemotherapy with or without surgical resection for stage III non-small-cell lung cancer: a phase III randomised controlled trial
- (2009) Kathy S Albain et al. LANCET
- Is neoadjuvant chemoradiotherapy a feasible strategy for stage IIIA-N2 non-small cell lung cancer? Mature results of the randomized IFCT-0101 phase II trial
- (2009) Nicolas Girard et al. LUNG CANCER
- Preoperative Therapy in Invasive Breast Cancer: Pathologic Assessment and Systemic Therapy Issues in Operable Disease
- (2008) Julie R. Gralow et al. JOURNAL OF CLINICAL ONCOLOGY
- Lung Adjuvant Cisplatin Evaluation: A Pooled Analysis by the LACE Collaborative Group
- (2008) Jean-Pierre Pignon et al. JOURNAL OF CLINICAL ONCOLOGY
- Adjuvant Paclitaxel Plus Carboplatin Compared With Observation in Stage IB Non–Small-Cell Lung Cancer: CALGB 9633 With the Cancer and Leukemia Group B, Radiation Therapy Oncology Group, and North Central Cancer Treatment Group Study Groups
- (2008) Gary M. Strauss et al. JOURNAL OF CLINICAL ONCOLOGY
- Effect of preoperative chemoradiation in addition to preoperative chemotherapy: a randomised trial in stage III non-small-cell lung cancer
- (2008) Michael Thomas et al. LANCET ONCOLOGY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started